tying up' the enzyme, while the partner-lactam inhibits the drug-target in the bacterial cell.
Introduction
Yersinia enterocolitica, an important enteric pathogen is represented by more than 50 serovars and 6 biovars viz. 1A, 1B, 2, 3, 4 and 5. Studies have shown that strains of Y. enterocolitica classified as biovar 1A represents more than one subspecies. [1] These are known to possess more than 17 distinct O-antigen types. [2] The strains of biovar 1A have generally been regarded as 'non-pathogenic' due to lack of known chromosomal determinants of virulence and the plasmid for Yersinia virulence plasmid. However, this has been challenged by many recent studies suggesting the potential pathogenicity of Y. enterocolitica biovar 1A. [3] [4] [5] Amoxicillin-clavulanate (AMC) is one of the most commonly prescribed antimicrobial against enteric infections. It has been devised to overcome β-lactamase mediated resistance in enteric bacteria and restore the efficacy of β-lactam antibiotics. Clavulanic acid acts as an inhibitor by forming stable intermediates with β-lactamases, 
Methods
The presence/absence of VFs in six clinical strains of Y. enterocolitica biovar 1A of two serotypes namely O: 6, 30 and O: 6, 30-6; 31 was compared with their minimum inhibitory concentrations (MICs) for AMC. These serotypes were selected as an earlier study showed that serovars O: 6, 30 and O: 6, 30-6, 31 of Y. enterocolitica biovar 1A were highly heterogeneous. [10] The details of the strains, their laboratory accession numbers, VFs and MICs for AMC are summarized in Table 1 .
Results and Discussion
We observed that the strains of serovar O: 6, 30-6;31 showed a similar relationship between the number of VFs and resistance to clavulanic acid as observed by Oteo et al. [9] for clinical isolates of E. coli. Lesser the number of virulence-related genes in strains of serovar O: 6, 30-6, 31 higher was their resistance to the β-lactamase inhibitor, resulting in a higher MIC for the AMC. However, strains of serovar O: 6, 30 displayed a heterogeneous relationship between the number of VFs and resistance to clavulanic acid. One clinical strain of serovar O: 6, 30 despite having only two VFs displayed low inhibitor resistance and consequently a low MIC for AMC. However, the other two strains with more VFs, exhibited more inhibitor-resistance, resulting in a higher MIC for AMC.
In a previous study, we also analyzed the promoters and complete coding sequence (CCDS) of β-lactamase gene blaA of each of the strain reported here. [8] From this, we inferred that the promoters and CCDS of β-lactamase gene (blaA) of all the three strains of serovar O: 6, 30 were identical as were the blaA of serovar O: 6, 30-6, 31. Thus, neither the variations in the β-lactamase gene sequence (blaA) nor the serological characteristics account for the unusual susceptibility to AMC displayed by the strains of the serovar O: 6, 30. Interestingly, the strains of serovar O: 6, 30 are usually reported from clinical cases of yersiniosis. [6] Whereas the strains of serovar O: 6, 30-6, 31 have been reported less commonly from clinical samples. [10] It has also been suggested that clinical strains of bioserovar 1A/O: 6, 30-6, 31 originated from environmental strains by host adaptation and genetic changes. [10] It might be speculated that given their environmental origin, the clinical strains of serovar O: 6, 30-6, 31 were exposed less to antibiotics compared to clinical strains of serovar O: 6, 30. Thus, the relationship between resistance to AMC and virulence-related factors might be dependent on characteristics other than serotypes or variations in gene sequences of β-lactamases.
This is the first study where the relationship between VFs and resistance to AMC has been investigated in strains of Y. enterocolitica biovar 1A. Further studies using biovars/serovars not represented in the present work, however, are required to corroborate these findings. 
